Perioperative Konzepte für resektable Adenokarzinome des Magens und des gastroösophagealen Übergangs

Die Operation stellt den einzigen kurativen Ansatz für resektable Adenokarzinome des Magens und des gastroösophagealen Übergangs dar. Selbst nach Resektion bleibt die Prognose aufgrund hoher Rückfallraten jedoch schlecht. Zur Verringerung von Rückfällen und damit zur Verbesserung des Überlebens wurden neoadjuvante und perioperative Systemtherapieansätze entwickelt. Die optimale Behandlung der nicht metastasierten Erkrankung bleibt allerdings weiterhin Gegenstand aktueller Untersuchungen.

Schlüsselwörter

Adenokarzinom des gastroösophagealen Überganges - Adenokarzinom des Magens - Magenkarzinom - lokalisiert - neoadjuvante Therapie - adjuvante Therapie

• Literatur

• 1 Santoro E. The history of gastric cancer: legends and chronicles. Gastric Cancer 2005; 8 (02) 71-74
• 2 Robinson JO. The history of gastric surgery. Postgrad Med J 1960; 36 (422) 706-713
• 3 DeVita Jr VT, Chu E. A History of Cancer Chemotherapy. Cancer Research 2008; 68 (21) 8643-8653
• 4 Macdonald JS, Smalley SR, Benedetti J. et al. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. New England Journal of Medicine 2001; 345 (10) 725-730
• 5 Fuchs CS, Niedzwiecki D, Mamon HJ. et al. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). JCO 2017;
• 6 Park SH, Sohn TS, Lee J. et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. JCO 2015; 33 (28) 3130-3136
• 7 Park SH, Lim DH, Sohn TS. et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 2021; 32 (03) 368-374
• 8 Cats A, Jansen EPM, Grieken NCT etl. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. The Lancet Oncology 2018; 19 (05) 616-628
• 9 Cunningham D, Allum WH, Stenning SP. et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine 2006; 355 (01) 11-20
• 10 Ychou M, Boige V, Pignon JP. et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. JCO 2011; 29 (13) 1715-1721
• 11 Schuhmacher C, Gretschel S, Lordick F. et al. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. JCO 2010; 28 (35) 5210-8
• 12 Al-Batran SE, Homann N, Schmalenberg H. et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. JCO 2017; 35 (Suppl. 15) 4004-4004
• 13 Shapiro J, Lanschot JJB van, Hulshof MCCM. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet Oncology 2015; 16 (09) 1090-1098
• 14 Reynolds JV, Preston SR, O’Neill B. et al. Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. JCO 2023; 41 (Suppl. 04) 295-295
• 15 Kelly RJ, Ajani JA, Kuzdzal J. et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine 2021; 384 (13) 1191-1203
• 16 Morad G, Helmink BA, Sharma P. et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 2021; 184 (21) 5309-5337
• 17 Janjigian YY, Shitara K, Moehler M etl al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet 2021; 398: 27-40
• 18 Sun JM, Shen L, Shah MA. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398: 759-771
• 19 Al-Batran SE, Lorenzen S, Thuss-Patience PC. et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. JCO 2022; 40 (Suppl. 16) 4003-4003
• 20 Patel SP, Othus M, Chen Y. et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine 2023; 388 (09) 813-823
• 21 Bang Y, Chung H, Xu J. et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. JCO 2009; 27 (Suppl. 15) 4556-4556
• 22 Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
• 23 Shitara K, Bang YJ, Iwasa S. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine 2020; 382 (25) 2419-2430
• 24 Hofheinz RD, Hegewisch-Becker S, Kunzmann V. et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. International Journal of Cancer 2021; 149 (06) 1322-1331
• 25 Hofheinz RD, Haag GM, Ettrich TJ. et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO. JCO 2020; 38 (Suppl. 15) 4502-4502
• 26 Wagner AD, Grabsch HI, Mauer M. et al. EORTC-1203-GITCG – the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 2019; 19 (01) 494
• 27 Stein A, Paschold L, Tintelnot J. et al. LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217). Annals of Oncology 2021; 32: S1331
• 28 Janjigian YY, Maron SB, Chatila WK. et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol 2020; 21 (06) 821-831
• 29 Rha SY, Lee C kun, Kim HS. et al. A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update. JCO 2021; 39 (Suppl. 03) 218-218
• 30 An JY, Kim H, Cheong JH. et al. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012; 131 (02) 505-511
• 31 André T, Tougeron D, Piessen G. et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol 2023; 41 (02) 255-265
• 32 Chalabi M, Verschoor YL, Berg J van den. et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Annals of Oncology 2022; 33: S1389
• 33 Pietrantonio F, Raimondi A, Lonardi S. et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). JCO 2023; 41 (Suppl. 04) 358-358